Clinical Trials Logo
  1. Home
  2. Minimal Change Disease
  3. NCT01084980

Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome — MCNS  

Minimal Change Disease Clinical Trial

Official title:
A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome

Clinical Trial Summary

The hypothesis of this study is that tacrolimus reduces the proteinuria in adult patient with minimal change nephritic syndrome.

Clinical Trial Description

A pilot study for comparative clinical trial on the therapeutic effect of tacrolimus (Prograf cap®) in adult patient with minimal change nephritic syndrome. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01084980
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 2/Phase 3
Start date June 2010
Completion date July 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Completed NCT04369183 - Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recruiting NCT02896270 - Valproic Acid for Idiopathic Nephrotic Syndrome Phase 2/Phase 3
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT05441826 - Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) Phase 2
Not yet recruiting NCT06405100 - Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD Phase 3
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting NCT03210688 - Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Phase 4
Completed NCT02592798 - Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Phase 2
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Recruiting NCT03068572 - Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD N/A
Recruiting NCT05650619 - Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Completed NCT00982072 - Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Phase 4
Terminated NCT04235621 - A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
Recruiting NCT03298698 - Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Phase 3
Recruiting NCT05003986 - Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Phase 2
Recruiting NCT05505500 - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Not yet recruiting NCT06315504 - Circulating Factors in Nephrotic Syndrome
Recruiting NCT03949972 - The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)